Category Archives: R&D

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

South African IP policy draft released seeking comments from public

International Trade and Economic Development division of South African Government has released the  Draft Intellectual Property Policy of the Republic of south Africa Phase 2017 and it is now publicly available for comments.  Access the draft policy here:   

Posted in IPR, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- James Love, Knowledge Ecology International

These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading

Posted in Delinkage, FTA, IPR, Patent, R&D, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Escaping Big Pharma’s Pricing With Patent-Free Drugs

Source: New York Times How’s this for a great deal? The United States government funded research and development of a new vaccine against Zika. But the Army, which paid a French pharmaceutical manufacturer for its development, is planning to grant exclusive … Continue reading

Posted in Patent, R&D, Uncategorized | Leave a comment

 The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?

 Lawmakers are concerned that giving a drug company a monopoly on the promising vaccine could make it unaffordable. 

Posted in Drug prices, Patent, R&D, Uncategorized | Leave a comment

US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices

By Frederick M Abbott*, IP Watch | 31/05/2017 The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. … Continue reading

Posted in Cancer, Patent, R&D, Uncategorized | Leave a comment

Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs

Source: Knowledge Ecology International The Supreme Court’s decision in IMPRESSION PRODUCTS, INC. v. LEXMARK INTERNATIONAL, INC.  has clarified that the United States has world wide exhaustion of patent rights.   According to Professor Fred Abbott, who knows a lot about this issue, and … Continue reading

Posted in Cancer, Delinkage, ISDS, R&D, Uncategorized, USFDA | Leave a comment